A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1590

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Teclistamab
DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Talquetamab

Sponsor

Janssen Research & Development, LLC